MiniMed Group, Inc. Common Stock
NASDAQ:MMEDMedical - Care Facilities
+$0.40 today
- Market cap
- $4.78B
- Beta
- -3.63
- P/E (TTM)
- -14.2
- EPS (TTM)
- -$1.91
Volume 4.70M
Average 0.95M
MMED Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
MiniMed Group, Inc. Common StockNASDAQ: MMED
Stock-Based Compensation · Q1 FY2026 · quarter ended Jul 2026
Stock-based compensation of $10M in Q1 FY2026
Q1 FY2026 stock-based compensation was $10M. Trailing-twelve-month stock-based compensation was $47M. Over 3 fiscal years it compounded at +9.5% a year.
Context
- Stock-based compensation amounted to 1.5% of revenue in FY2025, unchanged from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $10M or moves back toward the trailing-twelve-month quarterly average of $11.75M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 46M USD
- Year-over-year change
- +12.2%
- 3-year CAGR
- +9.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2026-04-24 | 46M | +12.2% |
| FY2024 | 2025-04-30 | 41M | +7.9% |
| FY2023 | 2024-04-30 | 38M | +8.6% |
| FY2022 | 2023-04-30 | 35M | — |
Stock-Based Compensation vs competitors
How MMED compares with its peers on the latest reported figures
- MMED's LTM Jul 2026 stock-based compensation of $47M is the 5th largest of the 7 companies compared; the peer median is $80.23M.
- Stock-based compensation amounts to 1.5% of revenue for MMED, versus a peer median of 5.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $496M | +14.8% | +8.8% | 1.3% | |
| LTM Jun 2026 | $162.4M | -2.3% | +8.1% | 3.3% | |
| LTM Mar 2026 | $82.55M | -21.3% | +2.8% | 8.0% | |
| LTM Jun 2026 | $77.9M | +22.1% | +15.3% | 2.6% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $47M | — | +9.5% | 1.5% |
| LTM Mar 2026 | $18.99M | +142.5% | +39.0% | 17.2% | |
| LTM Mar 2026 | $10.59M | +14.3% | +5.6% | 26.0% | |
MMEDVMiniMed Group, Inc. | — | — | — | — | — |
| Peer median (excluding MMED) | $80.23M | +14.6% | +8.4% | 5.7% | |
Competitors are the stored peer set for MMED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Apr 2023 | FY2023 Apr 2024 | FY2024 Apr 2025 | FY2025 Apr 2026 |
|---|---|---|---|---|
| Net Income | (92M) | (107M) | (198M) | (317M) |
| Depreciation & Amortization | 115M | 129M | 143M | 156M |
| Deferred Income Tax | (11M) | 3M | (2M) | (54M) |
| Stock-Based Compensation | 35M | 38M | 41M | 46M |
| Change in Working Capital | (90M) | (74M) | 122M | (166M) |
| Accounts Receivables | (70M) | (105M) | (66M) | (538M) |
| Inventory | (28M) | 5M | (19M) | (29M) |
| Accounts Payables | 14M | (4M) | 191M | 41M |
| Other Working Capital | (6M) | 30M | 16M | 360M |
| Other Non-Cash Items | 37M | 52M | 34M | 138M |
| Operating Cash Flow | (6M) | 41M | 140M | (197M) |
| Capital Expenditures | (167M) | (148M) | (193M) | (223M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (13M) | (5M) | 0 | 0 |
| Sales of Investments | 0 | 11M | 0 | 0 |
| Other Investing Activities | 0 | (15M) | 0 | (10M) |
| Investing Cash Flow | (180M) | (157M) | (193M) | (233M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 538M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 185M | 112M | 10M | 178M |
| Financing Cash Flow | 185M | 112M | 10M | 716M |
| Effect of Forex Changes | 0 | 0 | 0 | 1M |
| Net Change in Cash | (2M) | (4M) | (43M) | 287M |
| Free Cash Flow | (173M) | (107M) | (53M) | (420M) |
MiniMed Group, Inc. Common Stock
NASDAQ:MMED
Intrinsic Alpha fair value
Locked
Current Price
$16.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.